NHS England have approved the use of cannabis-based medicines for the first time. Epidyolex can now be prescribed to children with severe epilepsy syndromes and Sativex can be prescribed to individuals with multiple sclerosis.
Browsing: Epilepsy and seizure
A new therapeutic concept, which utilizes dynorphin-based gene therapy, has been developed and could suppress seizures at their site of origin and on demand.
Epidyolex® has gained approval from the European Commission for seizures associated with Lennox–Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
A promising new study could provide an early warning system to enable people with epilepsy to know when they are at risk of having a seizure.
Researchers have recently found that the brains of children with severe epilepsy can be compensated by rewiring regions of the visual cortex after surgery.
A Phase III study has shown that cannabidiol can reduce seizures by almost half in children with Dravet syndrome, a rare type of severe epilepsy.
The Epilepsy Society is calling for the UK government to regulate flashing images online. This will help to safeguard individuals with photosensitive epilepsy.
Researchers have developed a ‘pacemaker for the brain’, which can monitor and stimulate electric currents, potentially leading to novel treatments in individuals with neurological diseases.